Literature DB >> 8142665

Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer.

F Mavilio1, G Ferrari, S Rossini, N Nobili, C Bonini, G Casorati, C Traversari, C Bordignon.   

Abstract

Peripheral blood lymphocytes (PBLs) are key target cells for gene therapy of a number of inherited and acquired blood disorders. We have systematically compared four retroviral vectors, designed according to different strategies, for their efficiency in transfer and expression in human PBLs of the same reporter gene. The receptor gene used in the study codes for the human low-affinity nerve growth factor receptor (LNGFR), and is not expressed on the majority of human hematopoietic cells, thus allowing quantitative analysis of the transduced gene expression by immunofluorescence, with single cell resolution. Peripheral blood mononuclear cells (PBMCs), as well as human hematopoietic cell lines of myeloid and lymphoid origin, were transduced with the four vectors and analyzed for efficiency of gene transfer, integration and stability of vector proviruses, and LNGFR expression at both RNA and protein level. Fluorescence-activated cell sorter analysis of coexpression of LNGFR and lineage-specific cell surface markers was performed in transduced cell lines, PBLs, and T-cell clones to study gene expression on specific cell subpopulations. Although crucial differences were observed among different constructs, all retroviral vectors could transduce, under appropriate infection conditions, T-cell populations representative of the normal immune repertoire. Gene transfer and expression could be demonstrated also in circulating progenitors of mature T cells. Expression of the transduced gene was heterogeneous among cell populations infected with the different vectors, with optimal results obtained by two of the four constructs. Finally, we have devised a simple protocol based on vector-mediated gene transfer and positive immunoselection of the transduced cells that produces virtually 100% gene-modified cells. This may represent a crucial improvement in the way of designing efficacious protocols involving the use of gene-modified T lymphocytes in clinical studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142665

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

2.  Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

Authors:  P F Dijkers; R H Medema; C Pals; L Banerji; N S Thomas; E W Lam; B M Burgering; J A Raaijmakers; J W Lammers; L Koenderman; P J Coffer
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Elena Provasi; Anna Silvani; Marina Radrizzani; Claudia Benati; Elke Dammann; Annika Krons; Julia Kontsendorn; Joerg Schmidtke; Wolfgang Kuehnau; Nils von Neuhoff; Michael Stadler; Fabio Ciceri; Chiara Bonini; Arnold Ganser; Bernd Hertenstein; Eva M Weissinger
Journal:  Hum Gene Ther       Date:  2011-03-30       Impact factor: 5.695

Review 4.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

5.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Authors:  B A Bunnell; L M Muul; R E Donahue; R M Blaese; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 6.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

7.  gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.

Authors:  P D'Aloja; E Olivetta; R Bona; F Nappi; D Pedacchia; K Pugliese; G Ferrari; P Verani; M Federico
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector.

Authors:  S Sharma; M Cantwell; T J Kipps; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

9.  An efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinoma.

Authors:  Glenda Canderan; Paola Gruarin; Daniela Montagna; Raffaella Fontana; Gabriele Campi; Giulio Melloni; Catia Traversari; Paolo Dellabona; Giulia Casorati
Journal:  PLoS One       Date:  2010-08-09       Impact factor: 3.240

Review 10.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.